Challenges facing antibiotics on November 10, 2002

Challenges facing antibiotics on November 10, 2002

In 1928, British scientist Fleming discovered penicillin, a groundbreaking achievement that gave humanity the first proactive approach to bacterial infections. However, as the saying goes, “For every step forward, the devil takes two steps back”—pathogenic bacteria quickly developed resistance. In the early 1950s, drug-resistant Staphylococcus aureus emerged, posing a major challenge to anti-infective treatments. Since the 1980s, pathogenic bacteria have commonly produced β-lactamase, which can degrade the active ingredients in penicillin, cephalosporins, and other antibiotics, thereby reducing their antibacterial efficacy. Consequently, the dosage of penicillin has increased year by year—from 20,000 units in the 1950s to 200,000 → 800,000 → 2 million → 4 million units. As the devil grows stronger, so does the countermeasure. Medical scientists invented sulbactam preparations to significantly inhibit β-lactamase, known as β-lactamase inhibitors, thus partially countering bacterial resistance. Recently, clavulanic acid potassium preparations have also been discovered, with effects similar to sulbactam.